Holen Sie sich die Stockscreener-App
3.81
10.12%
0.35
Handel nachbörslich:
3.82
0.010
+0.26%
Schlusskurs vom Vortag:
$3.46
Offen:
$3.5
24-Stunden-Volumen:
3.18M
Relative Volume:
0.80
Marktkapitalisierung:
$512.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-217.44M
KGV:
-1.7558
EPS:
-2.17
Netto-Cashflow:
$-205.20M
1W Leistung:
-6.39%
1M Leistung:
-12.41%
6M Leistung:
+46.82%
1J Leistung:
-11.19%
1-Tages-Spanne:
$3.47
$3.88
1-Wochen-Bereich:
$3.35
$4.138
52-Wochen-Spanne:
$1.11
$5.17
Prime Medicine Inc Stock (PRME) Company Profile
Firmenname
Prime Medicine Inc
Sektor
Branche
Telefon
617-465-0013
Adresse
60 FIRST ST., CAMBRIDGE
Vergleichen Sie PRME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.81 | 616.83M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-04-08 | Eingeleitet | TD Cowen | Buy |
| 2024-04-03 | Eingeleitet | Wedbush | Outperform |
| 2024-01-16 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Eingeleitet | Citigroup | Neutral |
| 2023-10-09 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-07-31 | Eingeleitet | Guggenheim | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2022-11-14 | Eingeleitet | Goldman | Neutral |
| 2022-11-14 | Eingeleitet | JP Morgan | Overweight |
| 2022-11-14 | Eingeleitet | Jefferies | Buy |
| 2022-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prime Medicine Inc Aktie (PRME) Neueste Nachrichten
Prime Medicine (PRME.O) Sees Sharp Intraday Surge—What’s Behind the Move? - AInvest
Guggenheim cuts Prime Medicine stock price target to $5 from $18 - Investing.com Canada
Does Prime Medicine Inc. stock reflect fundamentalsJuly 2025 Earnings & Expert Curated Trade Ideas - thegnnews.com
Is Prime Medicine Inc. exposed to political riskUltra High Profit Potential - newsyoung.net
Prime Healthcare Services Receives Universal Credit Rating Upgrades from Fitch, Moody's and S&P - AInvest
Is Prime Medicine Inc. forming higher highs and higher lowsMulti-Bagger Picks in Progress - thegnnews.com
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Hold Rating - 富途牛牛
Chardan Capital Lowers Prime Medicine (NYSE:PRME) Price Target to $10.00 - Defense World
What makes Prime Medicine Inc. stock price move sharplyHigh Return Trade Roadmap with Setup Filters - Newser
Prime Medicine Inc. stock trendline breakdownFree Consistent Income Focused Trade List - Newser
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates - MSN
How high can Prime Medicine Inc. stock goFree Community Verified Stock Suggestions - Newser
Prime Medicine stock price target lowered to $10 at Chardan on cash update - Investing.com Canada
Prime Medicine, Inc.: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position - TipRanks
Prime Medicine Inc. stock retracement – recovery analysisFree Stock Market Entry Timing Signals - Newser
Prime Medicine Reports Q2 2025 Results and Strategic Updates - TipRanks
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
PRME Revenue Misses by 73% - AOL.com
Prime Medicine reports Q2 EPS (41c), consensus (34c) - TipRanks
Prime Medicine, Inc. SEC 10-Q Report - TradingView
Prime Medicine, Inc. Q2 operating expenses USD 54.492 million - MarketScreener
Alphabet Discloses $4.95 Million Equity Purchase in Prime Medicine via GV - TechGraph
Major Investment Alert: Prime Medicine, Inc. Sees Significant Share Purchase! - TipRanks
Prime Medicine (NYSE:PRME) Shares Gap Up Following Insider Buying Activity - Defense World
Why Prime Medicine Inc. stock attracts strong analyst attentionPrice Action Summary and Entry Strategy Guide - Newser
Prime Medicine Holds Special Stockholder Meeting - TipRanks
Bank of New York Mellon Corp Acquires 26,478 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Head to Head Comparison: Prime Medicine (NYSE:PRME) vs. Calidi Biotherapeutics (NYSE:CLDI) - Defense World
Prime Medicine (NYSE:PRME) Shares Gap Up on Insider Buying Activity - Defense World
Firm Advises Prime Medicine on IP Matters Related to $144 Million Public Offering - Wilson Sonsini
Prime Medicine Surges 8.5% Amid KDJ Golden Cross Signal and Biotech Sector Rally - AInvest
Prime Medicine (PRME.O) Sees Sharp Intraday Surge—What’s Driving the Move? - AInvest
Why is Prime Medicine Inc. stock attracting strong analyst attentionAchieve rapid capital gains with smart investing - Jammu Links News
What are the latest earnings results for Prime Medicine Inc.Free Consultation - Jammu Links News
What institutional investors are buying Prime Medicine Inc. stockGet insider insights into market trends - Jammu Links News
What drives Prime Medicine Inc. stock priceAchieve rapid financial growth with smart picks - Jammu Links News
What are Prime Medicine Inc. company’s key revenue driversAchieve breakthrough performance in the market - Jammu Links News
When is Prime Medicine Inc. stock expected to show significant growthUnlock your portfolio’s hidden potential - Jammu Links News
What analysts say about Prime Medicine Inc. stockStay informed with daily expert analysis - Jammu Links News
Is Prime Medicine Inc. a growth stock or a value stockInvest confidently with advanced analysis tools - Jammu Links News
What is the risk reward ratio of investing in Prime Medicine Inc. stockUnlock powerful market trend analysis - Jammu Links News
Is Prime Medicine Inc. stock overvalued or undervaluedInvest smarter with daily market updates - Jammu Links News
Major Stakeholders Make Bold Moves in Prime Medicine Stock! - TipRanks
Arch venture fund XII buys Prime Medicine shares worth $9.99m - Investing.com Nigeria
Arch venture fund XII buys Prime Medicine shares worth $9.99m By Investing.com - Investing.com South Africa
Prime Medicine shares rise 1.98% after-hours following the closing of a $144.2 million stock offering. - AInvest
Prime Medicine's $144.2M Equity Raise and Strategic Implications - AInvest
Prime Medicine Closes $144.2 Million Stock Offering - MarketScreener
Prime Medicine's Strategic Capital Raise: A Catalyst for Gene Editing Innovation and Shareholder Value - AInvest
Prime Medicine Announces Closing of Public Offering and - GlobeNewswire
Prime Medicine Secures $144M Funding Boost with Strategic Cystic Fibrosis Foundation Investment - Stock Titan
Finanzdaten der Prime Medicine Inc-Aktie (PRME)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):